Catheter Precision Inc (VTAK) Quote

she tried to run, lets see what a/h or tomorrow brings.

inching up now, let’s do this!

and they dump it, lol. holding for now.

and here we gooooo!!!!

vtak- hopped in premarket at….

…

the dip. huge volume just hit after i got in, lets do this.

$VTAK: Booommmmmmmm............ now $0.70

Sup here ?

Big move from $0.24 yesterday.

52wk high is $8 going back to last July 4th.

Almost 150Milly traded in the last 2 days.

Definitely worth watching.


GO $VTAK

VTAK..........................................................................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK........................................................a/h

Can't run very far if all there is are losses.

Seems like VTAK most important product is in the losses category?

VTAK..............................................a/h

VTAK...........................................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK: "Willi & Cathi Catheter" said THANK you!!
https://www.mentone-educational.com.au/simulation/clinical-skills-and-patient-care/catheterisation-and-urology/willi-and-cathi-catheterization-trainers

Did a mixed shelf offering a few hits .60 + 29%

VTAK..............https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK.....https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK...............................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK........................................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK: I'm OUT, nice profit!! (Damn MM's simply will NOT let it run!!) Now, I'm over on my Girl Friend, Ms. PEGY stock!!!)

VTAK: If they LET IT run, we got $10 long before Close today. (But they let @DRUG soar at will, with ZERO halts!!)

VTAK in a second time at 1.38
Out at 1.55 …f it can break $1.38 solid then pathway to $1.74 can be established.
1.74 established $1.97- $2.21 next area to consider

VTAK: Due to the past few days of MONSTERS runners, the NASDAQ, SEC, MM's, etc., now want to HOLD-IN-CHECK any super-soaring stock!!! DAMN-IT!!!!

VTAK: And Halt number THREE!!! (To the UP side!!!)

VTAK: I want my $10.00 Close here, TODAY!!!!!!

VTAK: Halted AGAIN. (In the UPWARD direction, this time???? Hopefully.)

VTAK: Halted (hopefully not in the CRASHING direction).

VTAK....................................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK: Can we at least get some decent SLOPPY-MAGNETS pulling on this puppy today??? PLEASE!!!

VTAK: Read-all-about-it!! (Courtesy of Bing's "CoPilot"!!)
https://copilot.microsoft.com/?FORM=hpcodx&showconv=1

GETTING SLOPPY

If it can break $1.38 solid then pathway to $1.74 can be established. Personally all out

MAGNET APPROACH

ORDER FLOW IMPROVING

$1.30 taking all off table +190%

ORDER FLOW LOOKING FUNKY WITHOUT MUCH SUPPORT

.70s dip paying off $1 dollar 2m floater

VTAK HAS A 2.38 MAGNET

VTAK: What????!!!!!

VTAK..................................https://stockcharts.com/h-sc/ui?s=VTAK&p=D&yr=0&mn=2&dy=12&id=p84071410134

New low again

Boom time

VTAK new 52 week low

VTAK.........................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

VTAK............................https://stockcharts.com/h-sc/ui?s=VTAK&p=W&b=5&g=0&id=p86431144783

$VTAK Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study

https://www.accesswire.com/892490/catheter-precision-inc-completes-enrollment-of-75-patients-in-locket-ii-study

FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that it has enrolled 75 patients in its Phase II LockeT Study, which is now expected to conclude in October 2024.

As previously disclosed, the three phases of the LockeT studies began in 2023 and are intended to show the product's safety and benefits. Phase I was completed in 2023 and showed that LockeT works for its intended purpose and that there were no safety events. Product roll-out began in the first half of 2024, while the Company continues Phase II of the product studies.

Phase II compares manual compression, the current standard of care, to LockeT, in a one-to-one randomized study planned to include up to 100 patients and is designed to provide further evaluation of its safety and effectiveness, as well as additional data such as potential pain reduction and cost savings benefits. Enrollment completion is expected in October 2024 when final data analysis will be available for later submission to a peer-reviewed publication.

$VTAK Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO

https://www.accesswire.com/889185/catheter-precision-inc-announces-the-completion-of-patient-follow-up-for-the-vivo-european-registry-and-new-product-evaluations-of-vivo

FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.

As previously disclosed, the EU registry enrolled 125 patients with an aim to gather real world data about the use and benefits of VIVO, outside of a rigorous clinical study. The data serves multiple purposes including fulfilling European regulatory requirements for on-going data collection, publication of multi-center data, and future development of studies and improvements to the VIVO technology, including a demonstration of the accuracy and benefits of VIVO for pre-procedure planning of ventricular ablation. The data is expected to become available in Q4 2024. In addition to the conclusion of the EU Registry, Catheter Precision continues the ongoing studies it has previously disclosed as part of its commitment to gathering and publishing clinical data for the company's two product lines, VIVO and LockeT.

The Company also announced additional initial evaluations of VIVO. During July, three new European hospitals are beginning product evaluations including Manchester University NHS, Wythenshawe Hospital (UK), Institute for Clinical and Experimental Medicine (Prague), and Cardinal Massaia Hospital (Italy). In addition, two new US hospitals in California and Washington have been in-serviced and are scheduled to begin VIVO procedures this month as part of such initial evaluations.

$VTAK Catheter Precision, Inc. Announces Effectiveness of 1-for-10 Reverse Stock Split


https://www.accesswire.com/888642/catheter-precision-inc-announces

FORT MILLS, SC / ACCESSWIRE / July 15, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on July 15, 2024. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X 609.

Pursuant to the reverse stock split, every 10 shares of the Company's issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through book entry on the Company's records will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares of common stock will be issued in connection with the reverse split. Stockholders of record who otherwise would be entitled to receive fractional shares, will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses).

The reverse stock split will reduce the number of issued shares of the Company's common stock from 9,012,518 shares to approximately 901,251 shares. Proportional adjustments will be made to the number of shares of the Company's common stock issuable upon exercise or conversion of the Company's equity awards and warrants and other convertible securities, as well as the applicable exercise price, to the extent applicable. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company's transfer agent, Equiniti Trust Company, via email at https://equiniti.com/us/ast-access/individuals and select GET HELP or by telephone at (800) 937-5449 or (718) 921-8124.

Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on May 16 2024, which is available free of charge at the SEC's website, www.sec.gov, and on the Company's website at https://catheterprecision.com.

"While the reverse stock split is primarily designed to help ensure our continued technical compliance with the NYSE American minimum stock price requirement and allow us to lower our Delaware franchise taxes, we also hope to broaden the base of potential investors in Catheter Precision as we strive for greater efficiencies, increased cash flow and profitable growth. The split also has no direct impact on our market capitalization," said David Jenkins, Chief Executive Officer.

$VTAK Catheter Precision, Inc. (NYSE American:VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024

https://www.accesswire.com/883834/catheter-precision-inc-nyse-american-vtak-reports-preliminary-unaudited-revenue-for-the-second-quarter-and-six-months-ended-june-30-2024

15% Quarter Over Quarter Growth - Initial Sales of LockeT Recorded

FORT MILL, SC / ACCESSWIRE / July 1, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Revenue for the quarter ending June 30, 2024.

Catheter Precision, Inc. recognized its first sales of LockeT in the quarter ending June 30, 2024 resulting in revenue of $40,500. An additional $54,340 of revenue was recognized in the quarter ending June 30, 2024 for sale of VIVO products. Total revenue for the quarter and six months ended June 30, 2024 was $94,840 and $176,923, respectively.

"We are pleased to announce these preliminary unaudited revenues", said David Jenkins, CEO and Executive Chairman of Catheter Precision. "The very initial results of the onboarding of our new sales team, completed with the hire of Marie Claude Jaques as our new Chief Commercial Officer during May, are showing promise. The pipeline of potential customers is established and growing, giving us good insight for future revenue growth."

$VTAK Catheter Precision, Inc. Announces Receipt of First Purchase Order for VIVO from Distributor in Middle East


https://www.accesswire.com/879363/catheter-precision-inc-announces-receipt-of-first-purchase-order-for-vivo-from-distributor-in-middle-east

FORT MILL, SC / ACCESSWIRE / June 20, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company announced that it has received its first purchase order from Qatar. As previously announced, an initial evaluation of the VIVO product was completed earlier this year at Hamad Medical Corporation Heart Hospital in Doha.

"VIVO is a tool that allows physicians to streamline ventricular ablation procedures potentially saving time and reducing patient complications", said Fatih Ayoglu, European Sales Manager. "We look forward to continuing this expansion strategy."

$VTAK Catheter Precision, Inc. Announces Receipt of LockeT Purchase Order for Eisenhower Medical Center, a Third California Hospital

https://www.accesswire.com/877810/catheter-precision-inc-announces-receipt-of-locket-purchase-order-for-eisenhower-medical-center-a-third-california-hospital

FORT MILL, SC / ACCESSWIRE / June 17, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced an additional purchase order for its newest product, LockeT. As previously announced the company has recently expanded its US sales and clinical team in preparation for the national product launch of LockeT.

After a successful evaluation, the newest purchase order comes from Eisenhower Medical Center in Ranchero Mirage, California. This purchase order marks the third new hospital in California to issue a purchase order since the beginning of May, and the second in the United States to move beyond evaluation and approve orders for future use.

"LockeT is a tool that enables physicians to streamline the end of their procedures both in the operating room and in the recovery room, potentially saving time and money", said Marie-Claude Jacques, Chief Commercial Officer. "This forward momentum adds to our confidence that the EP community will continue to increasingly recognize LockeT's value, and our new commercial strategy will succeed."